SCREENING ASSAY
    4.
    发明授权
    SCREENING ASSAY 有权
    筛选试验

    公开(公告)号:EP1604209B1

    公开(公告)日:2008-10-22

    申请号:EP04719437.8

    申请日:2004-03-11

    发明人: NILSSON, Fredrik

    IPC分类号: G01N33/68 C12Q1/37

    摘要: The present invention relates to a method for analysing a heterogeneous sample of proteins, peptides or fragments thereof, the method comprising (a) separating the heterogeneous sample of proteins, peptides or fragments thereof into heterogeneous classes by binding members of each class to a spaced apart defined location on an array, wherein members of each class have a motif common to that class; and (b) characterising the proteins, peptides or fragments thereof in each class.

    POLYPEPTIDE, VACCINE AND USE THEREOF
    5.
    发明公开
    POLYPEPTIDE, VACCINE AND USE THEREOF 审中-公开
    POLYPEPTIDE,IMPFSTOFF UND VERWENDUNG DAVON

    公开(公告)号:EP1879919A2

    公开(公告)日:2008-01-23

    申请号:EP06753524.5

    申请日:2006-04-28

    发明人: HOLMGREN, Lars

    IPC分类号: C07K14/71 C07K16/28

    摘要: The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising a whole angiomotin molecule or a fragment thereof which may be used to generate immune responses to angiomotin. The invention also provides antibodies specific for a whole angiomotin molecule or a fragment thereof for use in prophylactic or therapeutic treatments.

    摘要翻译: 本发明涉及阻止血管形成(例如血管发生)的预防或治疗方法,例如阻止肿瘤生长。 特别地,本发明涉及包含可用于产生对血管动蛋白的免疫应答的完整血管动蛋白分子或其片段的疫苗或药物。 本发明还提供了用于预防或治疗性治疗的整个血管动蛋白分子或其片段特异的抗体。

    A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION
    6.
    发明授权
    A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION 有权
    方法对于抗体功能分子进化

    公开(公告)号:EP1268801B1

    公开(公告)日:2004-06-23

    申请号:EP01925538.9

    申请日:2001-04-04

    摘要: The present invention provides a method for producing a polynucleotide sequence encoding an antibody variable domain, the variable domain comprising complementarity-determining regions (CDRs) located within a selected framework (the 'master framework'), the method comprising the steps of (a) providing at least one nucleic acid molecule encoding one or more CDRs and associated framework regions (the 'original framework'), (b) amplifying at least one CDR-encoding portion of the nucleic acid molecule(s) of step (a) using one or more pairs of oligonucleotides as amplification primers and (c) assembling a polynucleotide sequence encoding an antibody variable domain by combining the amplified CDR-encoding nucleotide sequences produced in step (b) with nucleotide sequences encoding said master framework, wherein the oligonucleotide primers of step (b) comprise nucleotide sequences which differ from the corresponding nucleotide sequences encoding said master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same.